ASPI

ASP Isotopes develops and commercializes advanced isotope separation technologies serving nuclear energy, quantum computing, medical imaging, and semiconductor manufacturing industries requiring specific isotopes unavailable through conventional enrichment processes. Headquartered in Washington, D.C., the company's proprietary Aerodynamic Separation Process technology separates isotopes based on subtle mass differences using specialized centrifuge designs achieving higher purity levels and energy efficiency compared to traditional methods including gaseous diffusion, laser isotope separation, and conventional ultracentrifugation. ASP Isotopes targets multiple high-value isotope markets including silicon-28 for quantum computing processors requiring ultra-pure materials minimizing quantum decoherence, enriched molybdenum-100 for medical isotope production supporting diagnostic imaging procedures, uranium isotopes for next-generation small modular reactors, and specialty isotopes for research applications. The company's business model involves developing separation technology through demonstration facilities proving commercial viability, securing customer commitments through long-term supply agreements, and constructing dedicated production facilities serving specific isotope markets. ASP Isotopes completed a merger with Airtest Capital in 2021 listing on NASDAQ and raised capital funding its silicon-28 enrichment facility in South Africa expected to produce quantum-grade silicon supporting emerging quantum computing hardware manufacturers. The company faces technical risks including scaling unproven separation processes to commercial production volumes, regulatory challenges navigating nuclear material handling requirements, and competition from established isotope suppliers and alternative separation technologies.